Compare HKIT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKIT | BYSI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | China | United States |
| Employees | N/A | 44 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 31.4M |
| IPO Year | 2018 | 2016 |
| Metric | HKIT | BYSI |
|---|---|---|
| Price | $2.44 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.8K | ★ 2.0M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.57 |
| 52 Week High | $8.80 | $2.44 |
| Indicator | HKIT | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 48.14 |
| Support Level | $2.36 | $0.67 |
| Resistance Level | $2.59 | $1.25 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 8.26 | 86.45 |
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.